NASDAQ:EVGNEvogene Stock Price, Forecast & News

$1.08

-0.06 (-5.26 %)

(As of 05/26/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.07

Now: $1.08▼

$1.14

50-Day Range

$0.92

MA: $1.10▼

$1.21

52-Week Range

$0.75

Now: $1.08▼

$1.83

Volume50,554 shs

Average Volume20,252 shs

Market Capitalization$27.81 million

P/E RatioN/A

Dividend YieldN/A

Beta0.87

Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. The company operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company also provides medical cannabis products. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF, Corteva, ICL, Monsanto, Bayer, and others. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Evogene.

2.3 Community Rank

Outperform Votes
Evogene has received 201 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Evogene has received 243 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Evogene has received 54.73% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote “Outperform” if you believe EVGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Evogene does not currently pay a dividend.
Dividend Growth
Evogene does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evogene insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 26.10% of the stock of Evogene is held by institutions.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Evogene is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evogene is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evogene has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Agricultural chemicals

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EVGN

Previous Symbol

CUSIPN/A

CIK1574565

Webwww.evogene.com

Phone972-8931-1900

Debt

Debt-to-Equity Ratio0.03

Current Ratio8.56

Quick Ratio8.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$750,000.00

Price / Sales37.08

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.34 per share

Price / Book0.46

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-18,110,000.00

Net Margins-2,405.31%

Return on Equity-33.55%

Return on Assets-27.98%

Miscellaneous

EmployeesN/A

Outstanding Shares25,750,000

Market Cap$27.81 million

Next Earnings DateN/A

OptionableNot Optionable

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.

Evogene (NASDAQ:EVGN) Frequently Asked Questions

How has Evogene's stock been impacted by COVID-19 (Coronavirus)?

Evogene's stock was trading at $0.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EVGN shares have increased by 9.1% and is now trading at $1.08. View which stocks have been most impacted by Coronavirus.

How were Evogene's earnings last quarter?

Evogene Ltd (NASDAQ:EVGN) issued its quarterly earnings results on Wednesday, March, 4th. The biotechnology company reported ($0.24) EPS for the quarter. The biotechnology company had revenue of $0.12 million for the quarter. Evogene had a negative net margin of 2,405.31% and a negative return on equity of 33.55%. View Evogene's earnings history.

Has Evogene been receiving favorable news coverage?

News coverage about EVGN stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evogene earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutEvogene.

Are investors shorting Evogene?

Evogene saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 73,800 shares, an increase of 64.7% from the April 30th total of 44,800 shares. Based on an average trading volume of 21,600 shares, the days-to-cover ratio is presently 3.4 days. Approximately 0.4% of the shares of the stock are sold short. View Evogene's Current Options Chain.

Who are some of Evogene's key competitors?

Some companies that are related to Evogene include CVR Partners (UAN), Wynnstay Group (WYN), Arcadia Biosciences (RKDA), Eden Research (EDEN), Bion Environmental Technologies (BNET), China Green Agriculture (CGA), SenesTech (SNES), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT) and ICL Group (ICL). View all competitors.

What other stocks do shareholders of Evogene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evogene investors own include Elbit Systems (ESLT), Galmed Pharmaceuticals (GLMD), Protalix Biotherapeutics (PLX), Portola Pharmaceuticals (PTLA), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), THERAPIX BIOSCI/S (TRPX), AbbVie (ABBV), Akari Therapeutics (AKTX) and Allena Pharmaceuticals (ALNA).

Who are Evogene's key executives?

Evogene's management team includes the following people:

Mr. Ofer Haviv, CEO & Pres (Age 53)
Ms. Dorit Kreiner, Interim Chief Financial Officer
Mr. Mark Kapel, Exec. VP of Technology (Age 42)
Dr. Eyal Emmanuel, Chief Scientific Officer (Age 46)
Ms. Sigal Fattal, Exec. Officer (Age 48)

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

Who are Evogene's major shareholders?

Evogene's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include UBS Group AG (5.27%), Moon Capital Management LP (1.09%) and Jane Street Group LLC (0.12%).

Which institutional investors are selling Evogene stock?

EVGN stock was sold by a variety of institutional investors in the last quarter, including Moon Capital Management LP, and UBS Group AG.

Which institutional investors are buying Evogene stock?

EVGN stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC.

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $1.08.

How big of a company is Evogene?

Evogene has a market capitalization of $27.81 million and generates $750,000.00 in revenue each year.

What is Evogene's official website?

The official website for Evogene is www.evogene.com.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff